Evolutionary Genomics, Inc. Stock
Stocks
FNAM
US30051F1012
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
OTC Markets
18:21:23 31/10/2025 +04
|
5-day change | 1st Jan Change | ||
| 0.000200 USD | -.--% |
|
-.--% | - |
| 09/03/23 | Evolutionary Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
| 09/03/23 | Evolutionary Genomics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
| Market Cap | 2.99M 2.58M 2.43M 2.21M 4.16M 284M 4.19M 28.73M 11.18M 145M 11.24M 11M 479M | P/E 2021 |
-1.34x | P/E 2022 | -2x |
|---|---|---|---|---|---|
| Enterprise Value | 6.16M 5.31M 5M 4.55M 8.56M 585M 8.61M 59.1M 23M 297M 23.13M 22.63M 986M | EV / Sales 2021 |
-
| EV / Sales 2022 | - |
| Free-Float |
67.35% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 year | 0 | 0 | |
| 3 years | 0 | 0 | |
| 5 years | 0 | 0.9 | |
| 10 years | 0 | 5.71 |
| Manager | Title | Age | Since |
|---|---|---|---|
Walter Messier
CTO | Chief Tech/Sci/R&D Officer | 71 | 01/01/2000 |
Steve Warnecke
CEO | Chief Executive Officer | 70 | 01/10/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Steve Warnecke
CHM | Chairman | 70 | 01/10/2014 |
| Director/Board Member | 76 | 01/01/2000 | |
Mark Boggess
BRD | Director/Board Member | 66 | 01/01/2010 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/05/22 | Exercice | Chief Executive Officer | 185,715 | 2.8074% | ||
| 23/05/22 | Exercice | Founder | 278,571 | 4.2111% | ||
| 23/05/22 | Exercice | Founder | 55,714 | 0.8422% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -.--% | -.--% | -99.96% | 1.33K | ||
| +0.66% | -1.02% | +3.23% | +17.46% | 49.74B | ||
| +2.09% | -0.71% | +452.73% | +498.77% | 44.98B | ||
| -1.09% | -0.41% | +35.40% | +15.17% | 42.52B | ||
| -0.26% | -4.71% | +17.19% | +71.67% | 40.78B | ||
| -0.48% | -0.84% | +16.25% | +49.80% | 32.89B | ||
| -1.06% | +2.87% | - | - | 17.09B | ||
| -1.81% | -5.02% | +22.65% | +113.24% | 16.28B | ||
| +0.22% | -1.51% | +16.81% | +26.22% | 14.4B | ||
| -2.05% | -5.14% | +72.89% | +34.69% | 13.48B | ||
| Average | -0.54% | -2.20% | +70.79% | +80.79% | 27.22B | |
| Weighted average by Cap. | -0.33% | -2.27% | +97.46% | +122.31% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | - | - |
| Net income | -2.79M -2.41M -2.27M -2.07M -3.88M -265M -3.9M -26.8M -10.43M -135M -10.49M -10.26M -447M | -1.93M -1.67M -1.57M -1.43M -2.69M -184M -2.7M -18.56M -7.22M -93.41M -7.26M -7.11M -310M |
| Net Debt | 3.53M 3.04M 2.86M 2.61M 4.91M 335M 4.93M 33.86M 13.18M 170M 13.25M 12.97M 565M | 3.17M 2.73M 2.57M 2.34M 4.4M 301M 4.43M 30.38M 11.82M 153M 11.89M 11.63M 507M |
Employees
3
- Stock Market
- Stocks
- FNAM Stock
Select your edition
All financial news and data tailored to specific country editions
















